Puretech Health’s (PRTC) top line advanced by more than half in the six months to June, as its internal segment secured new agreements with both Roche (ROG:CH) and Boehriner Ingelheim. The group, which develops early-stage biotherapeutic products, saw its operating loss narrow by a quarter year on year to $52.8m (£40m).
IC TIP:
Buy
at
271p